Guardant Health price to sales ratio GH

Market value divided by revenue over the last twelve months, since 2019.

Today, Oct 23, 2026: 19.2×
7-year median: 13.2×
Against its 7-year history: 63rd; percentile: 0 is its lowest day, 100 its highest
7-year range: 3.5× to 66.0×
Peer median: 6.7×

Guardant Health's price to sales ratio is 19.2× as of Oct 23, 2026.

That is above its 7-year median of 13.2×, close to the middle of its last 7 years.

Over that time it ranged from 3.5× in Apr 2024 to 66.0× in Aug 2019.

The median for 10 diagnostics and research stocks of a similar size is 6.7×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	19.2×	10.5×	20.6×
2025	14.4×	6.0×	15.1×
2024	5.4×	3.5×	6.7×
2023	6.0×	4.8×	8.8×
2022	6.5×	6.5×	26.0×
2021	29.6×	26.8×	66.0×
2020	47.5×	26.6×	49.3×
2019	40.1×	36.6×	66.0×

Against its peers

Companies in Medical - Diagnostics & Research nearest Guardant Health's size, closest first, today.

Company	Price to sales ratio
GHGuardant Health	19.2×
LHLabcorp	1.9×
DGXQuest Diagnostics	2.3×
MEDPMedpace	6.7×
RVTYRevvity	6.1×
MTDMettler-Toledo International	8.1×
ILMNIllumina	9.1×
IDXXIDEXX Laboratories	9.7×
WATWaters	9.6×
IQVIQVIA	2.7×
AAgilent Technologies	6.6×
Peer median	6.7×

Where Guardant Health ranks

#54of 61Diagnostics and research stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Guardant Health

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.